ストックスクリーナーアプリを入手
74.48
0.15%
-0.11
アフターアワーズ：
74.73
0.25
+0.34%
Astrazeneca PLC (AZN) 最新ニュース
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market to Witness Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire Inc.
AstraZeneca’s New Phase III Trial Targets Unresectable Pleural Mesothelioma - TipRanks
AstraZeneca’s Latest Clinical Study: Evaluating AZD5004’s Impact on Drug Interactions - TipRanks
AstraZeneca’s Ongoing Study on Olaparib for Advanced Ovarian Cancer: Market Implications - TipRanks
AstraZeneca’s Promising Phase II Study on AZD6234 for Diabetes Management - TipRanks
AstraZeneca’s Koselugo Study: Real-World Insights from Korea - TipRanks
AstraZeneca’s Andexanet Alfa Study: Real-World Insights and Market Implications - TipRanks
AstraZeneca’s New COPD Study: Potential Market Impacts and Investor Insights - TipRanks
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes - Financial Times
Swedish Stocks in North America – AstraZeneca Rises 0.8 Percent - MarketScreener
Is Now a Good Time to Reenter AstraZeneca PLC Depositary ReceiptMarket Momentum and Signal Alerts Suggest Reversal - beatles.ru
AstraZeneca’s Phase II Study on AZD0901: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s Promising Study on AZD9829 for Blood Cancers: Key Insights for Investors - TipRanks
AstraZeneca’s Olaparib Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
AstraZeneca’s New Study on HER2 Expression in Gynecological Cancers: What Investors Need to Know - TipRanks
AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging - insights.citeline.com
What makes AstraZeneca PLC Depositary Receipt stock price move sharplyOutstanding growth strategies - Jammu Links News
Is it the right time to buy AstraZeneca PLC Depositary Receipt stockBreakthrough wealth creation - Jammu Links News
AstraZeneca’s Latest Study on Asthma Inhalers: Key Insights for Investors - TipRanks
What are AstraZeneca PLC Depositary Receipt company’s key revenue driversMassive stock growth - Jammu Links News
How strong is AstraZeneca PLC Depositary Receipt company’s balance sheetGet timely advice on market trends - Jammu Links News
What is the risk reward ratio of investing in AstraZeneca PLC Depositary Receipt stockOutstanding yields - jammulinksnews.com
AstraZeneca’s AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension - The Globe and Mail
Proactive weekly health highlights: AstraZeneca, GSK, hVIVO, Avacta, and more - Proactive financial news
AstraZeneca’s Oral Drug Revolution: Could This Be the Future of Heart & Lung Treatments? - Smartkarma
AstraZeneca Can't Take Diabetes Drug IP Appeal To Top Court - Law360
AstraZeneca reports total voting rights of 1.55 billion ordinary shares - Investing.com
AstraZeneca’s New Study on Endometrial Cancer Treatment: Key Insights for Investors - TipRanks
AstraZeneca’s AZD5004: A New Hope for Obesity and Overweight Management - TipRanks
AstraZeneca’s Ongoing Study on New Breast Cancer Treatment Shows Promise - TipRanks
AstraZeneca’s PRIMROSE Study: A New Frontier in Cancer Treatment - TipRanks
AstraZeneca’s New Heart Failure Study: Potential Market Impact - TipRanks
AstraZeneca’s Promising Study on Advanced Cancer Treatments: A Market Overview - TipRanks
AstraZeneca’s Ongoing Study on Olaparib: Potential Market Implications - The Globe and Mail
AstraZeneca’s LYNPARZA Study: Monitoring Safety in Breast Cancer Treatment - The Globe and Mail
AstraZeneca’s Calquence Study: Ensuring Safety in Real-World Use - The Globe and Mail
AstraZeneca’s New COPD Study: Potential Market Impact - The Globe and Mail
AstraZeneca’s Phase 3b Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Breast Cancer Treatment - The Globe and Mail
AstraZeneca’s Promising Phase III Study in Metastatic Breast Cancer: What Investors Need to Know - TipRanks
AstraZeneca’s Latest Phase IIIB Study: A Potential Game-Changer in Advanced Breast Cancer Treatment - TipRanks
AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer in Cardiovascular Health - TipRanks
AstraZeneca’s Latest Study on AZD5004: Implications for Liver Impairment Treatment - TipRanks
AstraZeneca’s Tezepelumab Study: Real-World Impact on Asthma and Cough - TipRanks
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results? - Yahoo Finance
AstraZeneca Announces Updated Share Capital and Voting Rights - TipRanks
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock - Yahoo Finance
AstraZeneca’s GEMINI-NSCLC Study: A New Era in Lung Cancer Research - TipRanks
AstraZeneca’s eVOLVE-Cervical Study: A New Hope for High-Risk Cervical Cancer - TipRanks
AstraZeneca’s PHRASE-HF Study: A Game Changer in Heart Failure Treatment? - TipRanks
AstraZeneca’s Innovative Propellant Study: Market Implications and Future Prospects - TipRanks
AstraZeneca’s COPD Study: New Propellant Shows Promise - TipRanks
AstraZeneca’s GEMINI-PeriOp GC Study: A New Horizon in Cancer Treatment - TipRanks
AstraZeneca PLC (NASDAQ:AZN) Q2 2025 Earnings Call Transcript - Insider Monkey
Why AstraZeneca Stock Was Topping the Market on Tuesday - MSN
AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab - MSN
Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana - Yahoo.co
FIVE at FIVE: BAE, Taylor Wimpey, Arkle, Cornish Metal, AstraZeneca - Proactive financial news
AstraZeneca’s Asthma Study Completion: Market Implications and Insights - TipRanks
AstraZeneca’s New Study on Personalized Asthma Treatments in China: Market Implications - TipRanks
Stock Watch: Q2 Earnings Blowouts Resume At AstraZeneca And GSK - insights.citeline.com
AstraZeneca’s Promising Phase IIb Study on AZD3427: Market Implications - TipRanks
AstraZeneca gets clean bill of health from leading investment bank - Proactive Investors
大文字化:
|
ボリューム (24 時間):